Altimmune's Upcoming Financial Report
Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company specializing in novel peptide-based therapeutics for liver and cardiometabolic diseases, has announced that it will report its financial results for the third quarter of 2025 on November 6, 2025. This event will allow investors and stakeholders to gain insights into the company's financial health and progress in its research and development endeavors.
Conference Call Details
On the same day as the financial report, Altimmune management is set to host a conference call at 8:30 a.m. ET to delve into the financial outcomes and other significant business updates. During this call, management will provide a comprehensive overview of what these results mean for the future of the company and answer any questions from analysts and investors.
Live Webcast Access
The conference call will be accessible for live listening through Altimmune's Investor Relations website. This format ensures that attendees can follow along with the discussion in real-time, highlighting the company's commitment to transparency with its stakeholders.
What to Expect from the Update
As a leader in the development of therapies targeting liver and cardiometabolic conditions, Altimmune's call will also cover updates on its lead product candidate, pemvidutide. This innovative glucagon/GLP-1 dual receptor agonist is designed for treating metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder, and obesity. These conditions are increasingly prevalent, making Altimmune's research particularly relevant as healthcare providers look for effective solutions.
Significance of Pemvidutide
Pemvidutide marks a significant advancement in treatment options for individuals suffering from these metabolic diseases. By targeting multiple aspects of metabolic health, the potential for improved patient outcomes could be substantial, making the upcoming updates even more crucial for both patients and investors.
About Altimmune
Altimmune, Inc. is dedicated to advancing its pipeline of peptide-based therapeutics aimed at tackling cardiovascular issues and liver diseases. With a clear focus on innovation and effective treatments, the company is strategically positioned to impact the ever-evolving biopharmaceutical landscape.
Investor Relations
For those interested in following Altimmune's developments, their Investor Relations website will be regularly updated with pertinent information. This is a great resource for anyone looking to stay informed about the company's performance and strategic direction.
Contact Information
Should you have questions or need further information, the Investor Contact for Altimmune is Lee Roth from Burns McClellan, who can be reached at 646-382-3403 or via email. For media inquiries, Elliot Fox from Real Chemistry is also available for contact.
Frequently Asked Questions
What is the date of Altimmune's upcoming financial report?
Altimmune will report its third quarter 2025 financial results on November 6, 2025.
How can I access the conference call?
The conference call can be accessed through Altimmune's Investor Relations website on the day of the report.
What is pemvidutide?
Pemvidutide is Altimmune's lead product candidate targeting metabolic dysfunction-related conditions for which the company is developing treatments.
Who should I contact for investor inquiries?
Lee Roth from Burns McClellan is the Investor Contact, reachable at 646-382-3403.
Where can I find more information about Altimmune?
Additional information about Altimmune can be found on their official website or through their Investor Relations page.
